mScarlet/LUC Reporter Cell Line - NCI-H1299

The NCI-H1299 cell line is a highly characterized human model of non-small cell lung carcinoma (NSCLC), originally derived from a lymph node metastasis of a patient with large cell lung cancer. It serves as a cornerstone in thoracic oncology research, uniquely valued for its complete lack of endogenous p53 protein expression (homozygous partial deletion of the TP53 gene), making it an ideal baseline system for investigating p53-dependent pathways and the biology of aggressive, metastatic lung malignancies. The mScarlet/Luc Reporter Cell Line - NCI-H1299 is a sophisticated, stably transfected derivative explicitly engineered to simultaneously co-express both the exceptionally bright, monomeric red fluorescent protein mScarlet and firefly luciferase (Luc). This advanced dual-labeling construct ensures continuous, high-level expression of both functional reporter genes across sequential in vitro passages. Crucially, this stable genetic integration is achieved without compromising the fundamental cellular morphology, the distinct p53-null molecular profile, or the intrinsic tumorigenic and highly invasive capacity of the original parental NCI-H1299 cells.

The incorporation of this dual-reporter system significantly broadens the experimental utility of the NCI-H1299 model for comprehensive translational lung cancer research. For in vitro studies, the intense red fluorescence provided by mScarlet expression allows researchers to easily visualize cellular dynamics, accurately quantify proliferation rates, and seamlessly isolate specific cellular subpopulations using standard fluorescence microscopy and flow cytometry techniques. For in vivo applications, the robust luciferase activity serves as the optimal foundation for non-invasive, longitudinal tracking of primary tumor progression and distant metastatic dissemination through bioluminescence imaging (BLI). Because it is a human-derived cell line, the NCI-H1299-mScarlet/Luc model is typically engrafted into immunocompromised mice (such as athymic nude or NSG strains) to establish highly reliable subcutaneous xenografts, clinically relevant orthotopic intrathoracic models, or robust models of experimental pulmonary metastasis. This specialized reporter line represents an exceptionally valuable platform for evaluating the in vivo therapeutic efficacy of novel chemotherapeutic regimens, gene therapies designed to restore p53 function, and emerging biotherapeutics, facilitating the real-time, accurate quantification of localized tumor burden and disseminated disease in living subjects.